Brief: Targovax Announces That ONCOS-102 And Durvalumab Trial Successfully Completes Part 1 In Colorectal Cancer

Circio Holding ASA

13/10/2020 06:08

Oct 13 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX ANNOUNCES THAT THE ONCOS-102 AND DURVALUMAB TRIAL
SUCCESSFULLY COMPLETES PART 1 IN COLORECTAL CANCER
    * PRE-DEFINED DISEASE CONTROL EFFICACY THRESHOLD IN OVARIAN
CANCER
WAS NOT MET AND THIS COHORT WILL BE CLOSED FOR ENROLLMENT
    * TRIAL IS A COLLABORATION BETWEEN TARGOVAX, ASTRAZENECA
(LSE/STO/NASDAQ: AZN), CANCER RESEARCH INSTITUTE (CRI) AND
LUDWIG CANCER RESEARCH

Source text for Eikon:  ID:nWkr17nb19 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))